Searching for Biological Markers in People With Neurodegenerative Diseases Such as Alzheimer's and Parkinson's
Studies genes, proteins and other body markers in adults with neurodegenerative diseases.
Key facts
- Who runs it
- Ospedale Policlinico San Martino
- Where
- Genoa, ItalySee the site
- Trial code
- Registry title
- Omics Sciences for the Identification of Pathogenetic Mechanisms and Biomarkers in Neurodegenerative Diseases
- Status
- Recruiting
- People taking part
- 1,200 people, planned
- Started
- 28 Feb 2025
- Expected to end
- 17 Sept 2039
- Type of study
- Observational
- Record updated
- 25 November 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who have a neurodegenerative disease. It plans to enrol at least 1.200 people.
- Age
- 18 years and older
- Sex
- All sexes can join
- Disease stage
- A neurodegenerative disease. The listed conditions are Alzheimer disease, FTD, young-onset dementia, MCI, Parkinson disease and ALS.
Main reasons for not taking part
- People who do not have a neurodegenerative disease cannot join
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Patients suffering from neurodegenerative diseases
Who cannot take part
- Patients not suffering from neurodegenerative diseases
Where in Italy
- Ospedale Policlinico San MartinoGenoa, ItalyContact: Paola Mandich, MDTaking people
About the trial
What the trial wants to find out
The study aims to use 'omics' sciences, employing the most advanced technologies currently available, in order to identify pathogenic genomic variants, proteins and/or altered molecular pathways in neurodegenerative diseases and to obtain a new and more complete characterisation of subjects affected by the neurodegenerative diseases under study. Thanks to the integration of genomic, gene expression (transcriptomic and epigenomic), protein and metabolic data and clinical data, the study also aims to identify new markers for the diagnosis, prognosis, also in terms of response to therapy, and monitoring of neurodegenerative diseases.
Read full original descriptionShow less
The study involves the enrolment of at least 1.200 individuals with neurodegenerative disease.
The group in the trial
- Patients diagnosed with neurodegenerative diseases
The study aims to identify pathogenic genomic variants and/or altered molecular pathways in these patients by analysing the entire genome and integrating these data with gene expression data and/or epigenomic and/or protein expression data. The study also aims to identify new markers for the diagnosis and monitoring of neurodegenerative diseases by analysing collected biological samples such as blood and blood derivatives, including liquid biopsy approaches using the most advanced technologies available at the t
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Omics Sciences for the Identification of Pathogenetic Mechanisms and Biomarkers in Neurodegenerative Diseases
- Plain-language title
- Searching for Biological Markers in People With Neurodegenerative Diseases Such as Alzheimer's and Parkinson'sGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 25 November 2025